MedTrace Logo

A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors

NCT01963715 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-10-02

No results posted yet for this study

Summary

This is a Phase 1, first-in-human study to determine the recommended dose of IMGN289 in adult patients with advanced EGFR-positive tumors.

Conditions

  • EGFR Positive Solid Tumors

Interventions

DRUG

IMGN289

Sponsors & Collaborators

  • ImmunoGen, Inc.

    lead INDUSTRY

Principal Investigators

  • Andrea Vergara-Silva, MD · ImmunoGen, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2015-04-30
Completion
2015-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01963715 on ClinicalTrials.gov